Clinical outcomes and serologic response in solid organ transplant recipients with COVID-19: A case series from the United States

52Citations
Citations of this article
200Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The coronavirus disease 2019 (COVID-19) pandemic caused by SARS coronavirus 2 (SARS-CoV-2) has caused significant morbidity and mortality for patients and stressed healthcare systems worldwide. The clinical features, disease course, and serologic response of COVID-19 among immunosuppressed patients such as solid organ transplant (SOT) recipients, who are at presumed risk for more severe disease, are not well characterized. We describe our institutional experience with COVID-19 among 10 SOT patients, including the clinical presentation, treatment modalities, and outcomes of 7 renal transplant recipients, 1 liver transplant recipient, 1 heart transplant recipient, and 1 lung transplant recipient. In addition, we report the serologic response in SOT recipients, documenting a positive IgG response in all 7 hospitalized patients. We also review the existing literature on COVID-19 in SOT recipients to consolidate the current knowledge on COVID-19 in the SOT population for the transplant community.

Cite

CITATION STYLE

APA

Fung, M., Chiu, C. Y., DeVoe, C., Doernberg, S. B., Schwartz, B. S., Langelier, C., … Babik, J. M. (2020). Clinical outcomes and serologic response in solid organ transplant recipients with COVID-19: A case series from the United States. American Journal of Transplantation, 20(11), 3225–3233. https://doi.org/10.1111/ajt.16079

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free